Description
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis.[8][9] Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.[8]
It is approved for use in the United States for people aged two years and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene.[8] It is also approved for use in Canada, the European Union, and Australia.[9][11][2]
Reviews
There are no reviews yet.